Background: Reduced telomere length (TL) and structural brain abnormalities have been reported in patients with schizophrenia (SZ) and bipolar disorder (BD). Childhood traumatic events are more frequent in SZ and BD than in healthy individuals (HC), and based on recent findings in healthy individuals could represent one important factor for TL and brain aberrations in patients.
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Background: Pioneering views at the dawn of the GWAS era held that nodes of genetic convergence downstream of any individual molecule per se regulate genetic networks subserving the core neurophysiological elements affected in schizophrenia (SCZ [1]). These nodes of genetic convergence might be, for example, transcription factors or miRNAs representing entry points into biologically valid pathways that affect cellular, systemslevel and behavioral phenotypes. Since many of the SCZ risk variants are non-coding and may control gene expression, it is plausible that the regulatory elements of gene expression represent a mechanism of risk. Using Weighted Gene Co-expression Network Analysis (WGCNA), we have previously shown that genetic networks including SCZ risk genes indexed via co-expression quantitative traits loci (co-eQTLs) are associated with core neurophysiological systems-level processes affected in SCZ, like working memory brain activity patterns [2] . However, genetic regulatory elements linking risk genes with altered regulation of gene expression at multiple risk loci are still missing.
Methods:
In two RNA sequencing studies, we first identified a gene coexpression module enriched for miR-137 targets and for SCZ risk, validated it in a mouse cell model, and found that its co-eQTLs are associated with brain activity. In our first study, we computed polygenic scores obtained either combining co-eQTLs associated with target genes of miR-137 or SCZ risk variants within target genes of miR-137; then, we compared their effects on two neurobiological phenotypes of SCZ, i.e., brain activation during working memory and emotion recognition. In our second study, we adopted an approach agnostic of regulators and identified gene co-expression modules enriched for SCZ risk genes. Finally, we associated SCZ risk modules with treatment response to olanzapine in two patients' cohorts. Results: We found different neurobiological readouts of the two scores, i.e., polygenic risk for SCZ was associated with working memory, while coexpression scores were associated with emotion recognition. These results suggest that co-eQTLs index a different signal compared to SCZ risk variants, although both are associated with SCZ phenotypes. In the second study, SCZ risk genes were co-expressed to a significant extent and were co-regulated by miR-101, miR-374, and miR-28. Furthermore, in two independent samples of patients with SCZ, the co-eQTLs of a SCZ risk module were associated with the inter-individual variation between patients in terms of positive symptoms decrease following 1-month treatment. Discussion: These findings suggest that genetic risk for SCZ translates into illness via gene co-regulation pathways mediated by molecular factors potentially susceptible to genetic influences. Furthermore, these results suggest that data mining of the transcriptome can effectively stratify patients in terms of their neurobiological and clinical phenotypes. This is relevant to prospective approaches entailing personalized pharmacological treatment. 
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Background: Schizophrenia is highly heritable as shown by MZ/DZ twin comparisons and is calculated to be at about 80%, although if familial transmission were Mendelian, it would be considered 100%. Since the field of genetics has produced the needed technology to examine DNA at the molecular level (beginning in the 1980's), researchers have attempted to find a major gene for schizophrenia, without success. Once it was realized that the most likely underlying genetic mechanism is multiple gene variants of small individual effect, it was realized that large sample sizes would be needed to detect them. Thus, international collaborations were organized, the most important being the Psychiatric Genomics Consortium (PGC), now over 900 investigators having accumulated over 100,000 individual DNA samples. Methods: The most current analyses of these data comparing patients with schizophrenia to controls has now yielded over 250 genome-wide significant loci producing modest elevation in the risk for schizophrenia (unpublished data presented at the World Congress of Psychiatric Genetics 10/18; https://www.med.unc.edu/pgc/pgc-workgroups). However, when taken together the heritability due to these loci or SNPs (SNP-Based Heritability) is calculated to be only about 23% (Lee et al., 2012) . The difference between the overall heritability and the contribution of modest effect loci is thus 57%. This latter figure is the so called "missing heritability and likely due to mutations of large affect that segregate with illness within some families.
Recently we performed a sequencing study of families multiply affected with schizophrenia. Results: We found mutations present in all affecteds and no unaffecteds in 7 of 9 families (Homann et al., 2016) . These mutations were unique to Downloaded from https://academic.oup.com/schizophreniabulletin/article-abstract/45/Supplement_2/S161/5434864 by guest on 13 November 2019
